Zobrazeno 1 - 10
of 3 201
pro vyhledávání: '"dipeptidyl peptidase-4 inhibitor"'
Autor:
Masahiro Isogawa, Hisashi Makino, Cheol Son, Kunihiro Nishimura, Takumi Hirata, Shu Kasama, Yoshihiro Miyamoto, Michio Noguchi, Masato Kasahara, Kiminori Hosoda
Publikováno v:
BMC Endocrine Disorders, Vol 24, Iss 1, Pp 1-8 (2024)
Abstract Background While the Sodium-glucose co-transporter 2 (SGLT2) inhibitors and dipeptidyl peptidase-4 (DPP4) are widely used for the glycemic control in type 2 diabetes mellitus, the differences in the effects of SGLT2 inhibitors and DPP4 inhib
Externí odkaz:
https://doaj.org/article/3c30aa10af6145a49ad751da66897f47
Publikováno v:
JEADV Clinical Practice, Vol 3, Iss 1, Pp 226-232 (2024)
Abstract Background The prognosis of dipeptidyl peptidase‐4 inhibitor‐associated bullous pemphigoid (DPP‐4i‐BP) is variable, with some cases showing spontaneous remission after drug cessation and others showing worsening BP or developing infe
Externí odkaz:
https://doaj.org/article/2e125e55b52e48649ee7df9e59d461e3
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Introduction: Following the introduction of incretin-based drugs to the market, instances of acute pancreatitis have been reported, leading the FDA to mandate a warning label. Incretin-based therapy has been linked to a rare yet significant adverse e
Externí odkaz:
https://doaj.org/article/d82946e4340246c4adb8003cd2f5bd22
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Introduction: Nephrotoxicity represents a major complication of using doxorubicin (DOX) in the management of several types of cancers. Increased oxidative stress and the activation of inflammatory mediators play outstanding roles in the development o
Externí odkaz:
https://doaj.org/article/19d885e42bec45008bbfca4122bf4ee5
Publikováno v:
Kaohsiung Journal of Medical Sciences, Vol 39, Iss 10, Pp 1038-1044 (2023)
Abstract Several studies have reported an association between dipeptidyl peptidase 4 inhibitor (DPP4i), a commonly prescribed second‐line oral antihyperglycemic drug, and bullous pemphigoid (BP). However, the benefits of DPP4i withdrawal in patient
Externí odkaz:
https://doaj.org/article/5ea5f65044694fecbc777b8e688e969c
Autor:
Midori Sunada, Seiko Sugiyama, Yukiko Nakahara, Mariko Yamane, Rehito Mashiko, Takenobu Yamamoto, Yumi Aoyama
Publikováno v:
JEADV Clinical Practice, Vol 2, Iss 3, Pp 479-487 (2023)
Abstract Background Many reports have described the development of bullous pemphigoid (BP) following COVID‐19 vaccination. In dipeptidyl peptidase‐4 inhibitor‐associated BP (DPP‐4i‐BP), cessation of DPP‐4i appears to have a paradoxical ef
Externí odkaz:
https://doaj.org/article/f1d19178bb97485e824d85aaa316d9b9
Publikováno v:
American Journal of Ophthalmology Case Reports, Vol 32, Iss , Pp 101957- (2023)
Purpose: To report a rare Ocular Cicatricial Pemphigoid (OCP) case in a patient taking a Dipeptidyl Peptidase-4 Inhibitor (DPP-4 inhibitor), a medication used for the management of type 2 diabetes, for at least six years. Observations: A 64-year-old
Externí odkaz:
https://doaj.org/article/59edd01299f947d8988f8ff112966b81
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 168, Iss , Pp 115755- (2023)
Alzheimer’s disease (AD) and type 2 diabetes mellitus (T2D) share common features, including insulin resistance. Brain insulin resistance has been implicated as a key factor in the pathogenesis of AD. Recent studies have demonstrated that anti-diab
Externí odkaz:
https://doaj.org/article/73de303e56bf4610b8f3e9e60443e53f
Autor:
Małgorzata Łupina, Agnieszka Wąsik, Irena Baranowska-Bosiacka, Maciej Tarnowski, Tymoteusz Słowik, Piotr Listos, Jolanta Kotlińska, Danuta Kosik-Bogacka, Izabela Gutowska, Joanna Listos
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 5, p 3008 (2024)
Linagliptin is a selective dipeptidyl peptidase-4 (DPP-4) inhibitor that indirectly elevates the glucagon-like peptide-1 (GLP-1) level. The aim of the present study was to check whether linagliptin has an influence on neurotransmission in rat brain.
Externí odkaz:
https://doaj.org/article/dd983bbf8e3243e78f4944e070a2434b
Autor:
Shangyu Chai, Ruya Zhang, Richard David Carr, Carolyn F. Deacon, Yiman Zheng, Swapnil Rajpathak, Jingya Chen, Miao Yu
Publikováno v:
Frontiers in Endocrinology, Vol 14 (2023)
AimsGlucose-dependent insulinotropic polypeptide (GIP) confers a variety of metabolic benefits in type 2 diabetes mellitus (T2DM). This meta-analysis was conducted to investigate the impact of dipeptidyl peptidase 4 (DPP4) inhibitors on GIP levels in
Externí odkaz:
https://doaj.org/article/c5d6fcb6c29c4a16a44ab5511b0fe22d